





Background

 Chronic Lymphocytic Leukemia (CLL) is a common B-cell lymphoproliferative disorder.

• PI₃K- δ inhibitors are effective therapies for CLL.

• PI₃K-δ inhibitors include Idelalisib (FDA approved) and Umbralisib (TGR-1202 - in clinical studies).

• PI₃K-δ inhibitors cause CLL cell apoptosis, cytotoxicity, and reduction of AKT phosphorylation *in* vitro.

• Monocyte-derived cells, also known as "nurse like cells" (NLC) are considered to be a component of the CLL lymph node microenvironment.

• Clinically, PI₃K-δ inhibitors cause initial lymphocytosis thought to be due to a disrupted CLL cell – NLC interaction, with egress of CLL cells from the lymph node microenvironment.

• The direct effect of PI3K- δ inhibitors on monocytes is unknown.


Hypothesis

PI₃K- δ inhibitors induce monocyte cytotoxicity, inhibit differentiation towards M1 or M2 polarized monocytes, and reduce monocyte AKT phosphorylation.

PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation

Daphne R. Friedman, Alicia Volkheimer, Eross Guadalupe, Dave Maryanski, Hari P. Miskin, J. Brice Weinberg

Durham VA Health Care System and Duke University Medical Center - Durham, North Carolina, USA **TG Therapeutics, Inc. - New York, NY**



Methods

Monocytes were isolated from normal donors using negative selection (RosetteSep monocyte). Cytotoxicity was measured using the MTS reagent. Primary purified monocytes were incubated ± M-CSF $(10 \text{ ng/mL}) \pm \text{PI}_{3}\text{K-}\delta$ inhibitor (at 1.25 to 20 μ M) for three days. Monocyte differentiation was measured using flow cytometry to measure expression of CD14, CD206, CD163, CD124, CD80, and CD86. Primary purified monocytes were incubated first with M-CSF (10 ng/mL) for three days, then washed and incubated \pm IL-10 (20 ng/mL) \pm PI3K- δ inhibitor (10 μ M) for three days. • AKT phosphorylation was measured using flow cytometry after whole blood incubation with LPS (50 ng/mL) or M-CSF (100 ng/mL) \pm PI3K- δ inhibitor (10 μ M). • Statistical analyses were performed in the statistical environment, R.

Duke University School of Medicine

Conclusions

• PI₃K-δ inhibitors affect signal transduction and viability, but not differentiation, of normal monocytes in vitro.

• There were differences noted between Idelalisib and Umbralisib with regards to the extent of cytotoxicity induced and inhibition of M-CSF induced pAKT.

• The clinical benefit and initial lymphocytosis seen with PI3K- δ inhibitors in CLL may be related in part to direct effects on monocytederived cells.

• Inhibition of monocyte function and/or induction of monocyte toxicity *in vivo* may suppress the innate immune system, increasing the risk of atypical infections in CLL patients taking PI3K- δ inhibitors.

• The direct effects of PI3K- δ inhibitors on monocytes suggests these drugs may have efficacy in monocytic neoplasms or in other malignancies with monocyte derived cells in the tumor microenvironment.

References

• Burger JA et al, "Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cellderived factor-1." Blood, 2000.

Brown, JR et al, "Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 δ , for relapsed/refractory chronic lymphocytic leukemia." Blood. 2014.